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Abstract. Wide local excision (WLE) of tumors with negative margins remains a challenge because surgeons
cannot directly visualize the mass. Fluorescence-guided surgery (FGS) may improve surgical accuracy; however, conventional methods with direct surface tumor visualization are not immediately applicable, and properties of tissues surrounding the cancer must be considered. We developed a phantom model for sarcoma
resection with the near-infrared fluorophore IRDye 800CW and used it to iteratively define the properties of connective tissues that typically surround sarcoma tumors. We then tested the ability of a blinded surgeon to resect
fluorescent tumor-simulating inclusions with ∼1-cm margins using predetermined target fluorescence intensities
and a Solaris open-air fluorescence imaging system. In connective tissue-simulating phantoms, fluorescence
intensity decreased with increasing blood concentration and increased with increasing intralipid concentrations.
Fluorescent inclusions could be resolved at ≥1-cm depth in all inclusion concentrations and sizes tested. When
inclusion depth was held constant, fluorescence intensity decreased with decreasing volume. Using targeted
fluorescence intensities, a blinded surgeon was able to successfully excise inclusions with ∼1-cm margins from
fat- and muscle-simulating phantoms with inclusion-to-background contrast ratios as low as 2∶1. Indirect, subsurface FGS is a promising tool for surgical resection of cancers requiring WLE. © 2017 Society of Photo-Optical
Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JBO.22.12.121613]
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1

Introduction

Surgical resection remains a primary treatment for many types
of cancer. However, conventional open, white light-guided
surgical techniques are plagued by suboptimal recurrence rates,
resulting from residual cancer cells left at the cancer site.
Numerous advances for surgical resection have been proposed,
one of which is the use of fluorescence guidance to aid in
identifying tumor boundaries and residual cancer cells.1
Fluorescence-guided surgery (FGS) has proven particularly useful in cancers of the brain,2–5 bladder,6–8 and head and neck,9,10
because these cancers are present on the organ surface, and can
be viewed directly with administration of fluorescent probes
combined with specially equipped surgical microscopes.
However, many tumors lie below the surface of the organ
and are, therefore, not currently amenable to direct fluorescence
visualization.
Many subsurface tumors, such as sarcomas, require tumor
excision as a single, complete mass with a zone of normal tissue
surrounding the tumor, termed a wide local excision (WLE) with
negative margins. The presence of cancer cells at the surface of
the excised mass defines a positive margin and is associated with
increased recurrence rates and decreased survival rates.11–14

*Address all correspondence to: Kimberley S. Samkoe, E-mail: kimberley.s.
samkoe@dartmouth.edu
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Unfortunately, positive margin rates following sarcoma resection with curative intent remain in the range of 22% to
34%.11–13 WLE of subsurface tumors presents several barriers
to conventional direct fluorescence visualization because a margin of normal tissue must be maintained around the mass. Useful
application of FGS to sarcomas would provide the surgeon with
real-time feedback about tumor location and margin thickness.
However, successful implementation of FGS for sarcoma
resection will require more sophisticated modeling, taking
into consideration the absorption and scattering properties of
the investing connective tissues—generally fascia, muscle, and
fat—with considerations for tumor size and probe uptake both in
the tumor and surrounding tissues.
Numerous fluorescent probes have been utilized for oncologic surgery in an off-label fashion2–9 or investigated at the preclinical stage;15–23 however, approval of fluorescent probes is
slowed by the high cost of drug development. The introduction
of good manufacturing practice (GMP)-produced IRDye
800CW (LI-COR Biosciences, Inc., Lincoln, Nebraska) has
renewed drug development for FGS applications.24–26 One
resultant drug is ABY-029, a synthetic anti-epidermal growth
factor receptor (EGFR) affibody molecule covalently bound
to IRDye 800CW. ABY-029 has several advantages that
1083-3668/2017/$25.00 © 2017 SPIE
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make it an excellent candidate for future FGS applications. First,
human tissue optical properties in the near-infrared region,
including reduced water absorption, scattering, and autofluorescence, allow for deeper sampling volumes and increased fluorescence contrast as compared to other wavelengths. Second,
the smaller affibody-based molecule provides better enhancement in peripheral tissues compared to larger antibody-based
compounds.27 Third, the excretion kinetics of ABY-029 is
fast, resulting in optimal contrast ratios in the order of hours
compared to days as is the case for antibody-based
compounds.28 We have tested ABY-029 rigorously in our
laboratory for toxicity,25 as a single-fluorescent agent in glioma
detection28 and in paired-agent imaging of several EGFR
expressing cancers.29–32 ABY-029 received eIND (#122681)
approval status in 2016, and the GMP form of ABY-029 was
produced for an ongoing phase-0 clinical trial for recurrent
glioma resection (NCT0291925).
ABY-029 is a promising agent for targeting soft tissue sarcomas, which overexpress EGFR in 43% to 78% of cases,33–37
and the ability of this agent to tag EGFR-positive sarcomas is
currently being investigated in a phase-0 clinical trial at our
institution (NCT03154411). However, to develop indirect, subsurface visualization methodologies for use in WLE applications, modeling, and validation are required in phantom and
animal models. Furthermore, an advanced surgical imaging system must be selected and tested appropriately for detection of
the fluorophore. There are several open-field preclinical and
United States Food and Drug Administration (FDA)-approved
FGS systems capable of imaging near-infrared fluorophores,
as discussed thoroughly in our recent review.38 One of these systems, the SPY-Q (Novadaq, Mississauga, Canada), FDAapproved for indocyanine green imaging, has been used by
the Rosenthal group for phase I imaging of cetuximab-IRDye
800CW in head and neck cancer resection. 9,39 A second system,
the Solaris by PerkinElmer (Waltham, Massachusetts), has several advantages over the SPY system, including fluorescence
background correction that increases instrument sensitivity
(∼1 nM). The Solaris is not currently FDA-approved but
may be a strong candidate for future approval.
In this study, we present foundational work defining early
methods for FGS application to cancers requiring WLE using
the Solaris fluorescence image-guided surgery system. Here,
we compare the depth sensitivity and accuracy of the Solaris
with two preclinical systems specifically made by LI-COR
Biosciences, Inc. (Lincoln, Nebraska) to image IRDye
800CW—the Pearl Impulse and Odyssey CLx. We pursued
two primary aims: (1) to delineate the changes in observed
fluorescence of IRDye 800CW in human tissue-simulating
phantoms in relation to tumor size, tumor depth, bulk tissue
type, and imaging system and (2) to investigate the ability of a
surgeon, blinded to the location of a tumor-simulating inclusion
and guided only with tumor depth modeling data from aim 1,
to excise a fluorescent inclusion with ∼1-cm negative margins
using the Solaris imaging system.

2
2.1

Methods
General Preparation of Phantom Components

All inclusions and phantoms were made with 10% w/v gelatin
(G2500, Sigma-Aldrich, St. Louis, Missouri). Powder gelatin
was mixed with distilled water, heated to ∼60°C in a microwave,
and stirred vigorously while cooling to ∼30°C. Appropriate
Journal of Biomedical Optics

Table 1 Gelatin-based phantom preparation parameters.

Phantom properties
Gelatin
(%, w/v)

Blood
(%, v/v)

Intralipid
(%, v/v)

Tumor/inclusion

10

1

1

Muscle

10

2

1

Fat

10

0.5

0.75

Simulated tissue type

amounts of blood, intralipid, and fluorophore (Table 1) were
then added, and the mixtures were poured into suitable molds
and cooled in an ice bath. Whole bovine blood (Lampire
Biological Laboratories, Inc., Pipersfield, Pennsylvania) was
used as an absorbing agent in the physiological range in connective tissues of 0% to 2%, where 1% of blood at 800 nm
has an absorption coefficient (μa ) of 0.0004 mm−1 and is
equivalent to ∼20 μM total hemoglobin.40,41 Intralipid (Baxter
Healthcare Corporation, Deerfield, Illinois) was used as a scattering agent in the physiologically relevant range of 0.5% to 1%,
where 1% of intralipid at 800 nm has a scattering coefficient (μs0 )
of 1.0 mm−1 .40,42 All phantoms were stored at 4°C until
imaging.

2.2

Preparation of Well Phantoms for Screening
Bulk Tissue Properties

Five-milliliter volume wells (4 × 4) were created in black
Delrin® plastic. A panel of connective tissue-mimicking gelatin
phantoms was created, with each well containing 50-nM IRDye
800CW. The rows had varying blood (0.5%, 1%, 2%, and 5% v/
v) as an absorbing agent, and the columns had varying intralipid
(0.5%, 0.75%, 1%, and 1.5% v/v) as a scattering agent.40–42 The
4 × 4 wells were imaged using the 750-nm channel on the
Solaris imaging system. The regions-of-interest (ROIs) were
created to encompass the entire well, and the average fluorescence intensity per pixel was determined using the “measure”
function in Fiji.43–45

2.3

Preparation of Wedge Phantoms for Imaging
Inclusion Depth

Wedge-shaped phantoms were used to study the effect of tumor
and tissue properties on depth of imaging. We created this model
in three parts: inclusion, bottom base layer, and upper wedge
layer (Fig. 1). The inclusion was made with tumor physical
properties (Table 1) reflective of the absorption and scatter in
human connective tissue40–42 and with varying size and fluorescent attributes depending on the particular experiment (Table 2):
(1) background tissue properties, (2) inclusion concentration,
and (3) inclusion size. Disposable serological pipettes (Corning
Inc., Corning, New York) were used to create cylindrical inclusions by coating the inside with vegetable oil and then filling the
entire pipette with the gelatin inclusion mixture. Once cooled,
the gelatin inclusion was removed by pulling on the cotton filter
or pushing out with forced air. The bases were cast as positive
molds in clear rectangular containers (70 mm × 125 mm,
300-mL volume). The inclusions were placed into the base by
cutting an indentation such that the top of the inclusion was
flush with the top surface of the base [Fig. 1(a)]. The wedges
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(d)

Odyssey

Pearl

(c)

(b)

Solaris

(a)

(e)

Fig. 1 Imaging wedge phantoms to determine limits of imaging depth.
(a) Bases (2-cm high) with a fluorescent cylindrical inclusion were
placed on top of a positioning wedge. (b) A tissue-matched wedge
was placed on top, such that the imaging surface was flat. The
wedge contained no fluorophore (infinite IBR) or 3∶1 IBR. A representative fat, infinite IBR, 8-mm diameter inclusion phantom imaged on
the (c) Solaris, (d) Pearl, and (e) Odyssey. The red dashed line indicates the ROI to determine intensity profile of the wedge.

were made in the same rectangular mold but angled such that the
inclusion depth varied from 0.5 to 3 cm [Fig. 1(b)]; these were
designed to simulate muscle and fat tissues (Table 1).
For imaging on the Solaris (750-nm channel) and Pearl
Impulse (800-nm channel), the base and wedge were placed
on a clear positioning wedge such that the uppermost surface
was a parallel planar surface [Fig. 1(b)]. For imaging on the
Odyssey CLx system (800-nm channel), the wedge was placed
upside down, such that the imaging surface was flush on the
scanning bed, and the base was placed upside down on the
wedge. The specifications for each system are noted in Table 3.
For each image captured, a straight line ROI was created over
top of the inclusion, down the center of the phantom [Figs. 1(c)–
1(e)]. The “plot profile” function in Fiji43–45 was used to create a
line profile of fluorescence intensity over the length of the phantom. The length of the phantom was converted to depth in centimeters and plotted against fluorescence intensity. In the
inclusion size study (Table 2), the 3∶1 inclusion-to-background
ratio (IBR) condition did not have a uniform baseline for the
control condition (0 mm). Therefore, the fluorescence intensity,
I fl , of each plot profile in this group was modified to achieve
a flat-field corrected (FFC) fluorescence intensity, I fl ðFFCÞ,
using the following equation:

I fl ðFCCÞ ¼

EQ-TARGET;temp:intralink-;e001;326;499

I fl − I fl ðC∞ Þ
;
I fl ðC3∶1 Þ − I fl ðC∞ Þ

(1)

where I fl ðC∞ Þ and I fl ðC3∶1 Þ are the fluorescence intensities from
the no inclusion control conditions of the infinite and 3∶1
Table 2 Experimental phantom parameters for imaging depth in wedge phantoms.

Inclusion parameters

Experimental variable

Base parameters

IRDye 800CW
(nM)

Diameter (mm)

Blood (%, v/v)

Intralipid
(%, v/v)

Wedge parameters

Blood (%, w/v)

Intralipid
(%, w/v)

IRDye
800CW (nM)

0, 0.5, 1, 2

0.5, 1

0

Background tissue properties

8

50

Tumor/inclusion

Inclusion concentration

8

0, 5, 10, 20, 50

Muscle and fat

Muscle and fat

0

0, 4, 6, 8, 13, 17

50

Muscle and fat

Muscle and fat

0, 16.7

Inclusion size

Table 3 Imaging system specifications.

Imaging system
Parameter

PerkinElmer Solaris

LI-COR Pearl Impulse

LI-COR Odyssey CLx

Open-air, broad beam

Black box, broad beam

Black box, flatbed scanner

White light

Solid-state diode laser

Solid-state diode laser

743SP

785

785

770 to 809

820LP

820LP

Dynamic range

16 bit

22 bit

22 bit

Focal distance

75 cm

Not specified (∼25 to 30 cm)

0 to 4 mm

Fluorescence cCMOS camera

CCD, thermoelectrically cooled

Silicon avalanche photodiode

Imaging setting
Excitation source
Excitation wavelength
Emission

Detectors/camera

Journal of Biomedical Optics
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contrast wedges. Depth of imaging was determined by linearizing each line profile by taking the natural logarithm of the fluorescence intensity and fitting for the intersection with the
nonfluorescent control condition.

2.4

Preparation of Surgical Phantoms

Inclusions with 50-nM IRDye 800CW were created by pouring
cooled gelatin solution (1% blood and 1% intralipid) into disposable tissue embedding molds (22 mm × 22 mm, Electron
Microscopy Sciences, Hatfield, Pennsylvania) with 6-0 silk
sutures placed through the center to allow for positioning at
a later time. The solution was allowed to cool on ice, and
then the molds were frozen and stored at −80°C. Varying concentrations of background IRDye 800CW (0, 5, 10, 16.7, and
25 nM) were added to the fat- or muscle-simulating gelatin
solutions, such that the IBRs were ∞, 10∶1, 5∶1, 3∶1, and
2∶1, respectively (n ¼ 3 for each ratio). Frozen inclusions were
then removed from the molds and tethered via the sutures in
large cylindrical polypropylene containers (110-mm diameter,
140-mm height, and 1000-mL volume). In a set of surgical
test phantoms, inclusions were placed in the center of the container at ∼10 mm from the bottom. In a separate set of surgical
dissection phantoms, the inclusions were placed at random locations and ranging from 10 to 30 mm from the bottom. The liquid
phantom solution was then poured into all containers to an
approximate height of 60 mm, allowing the liquid to cover
∼30 mm above the top of the inclusion for the surgical test
phantoms, and ranging from 10 to 30 mm above the top of
the inclusion for the surgical dissection phantoms. The phantom
containers were cooled on ice and then stored overnight at
4°C. Phantom parameters are summarized in Table 4.
2.4.1

Surgical test phantom imaging

Imaging was performed on Solaris (PerkinElmer) and Pearl
Impulse (LI-COR) imaging systems. The 750- and 800-nm
channels were utilized for the Solaris and Pearl, respectively.
To determine the effect of volume on observed fluorescence,
images of each phantom were captured on both systems, and
then ∼5 mm was trimmed from the top surface. This process
of imaging and trimming was repeated for three additional
times, until ∼20 mm had been removed and ∼10 mm remained
above the inclusion. Subsequently, holding the inclusion constant in the center of the phantom (∼10-mm depth to inclusion),
the sides of the phantom were trimmed and images captured.
Five consecutive trimming-imaging sequences were performed
until the phantom was reduced to a cube. Volumes were calculated by subtracting water displacement of the removed gel from

the total volume of the phantom. Last, once reduced to a cube,
each side of the remaining phantom was imaged. After all of the
images were captured, the phantoms were then bisected in the
horizontal and vertical planes, and the margins (distance from
surface to inclusion) for each side were measured with a manual
caliper. An ROI capturing the inclusion was drawn on all
images, and average fluorescence values were recorded. The
effect of volume on the fluorescence signal was investigated
by plotting the average ROI fluorescence intensity against volume with decreasing depth to inclusion and then with decreasing
side volume. The targeted fluorescence signal for dissection was
determined by plotting the measured margin thickness against
the natural logarithm of the recorded fluorescence intensity
and fit for a target margin thickness of 10 mm.
2.4.2

Surgical phantom dissection

An orthopaedic surgeon (author E.R.H.) was provided targeted
fluorescence values (Table 5) representing the expected fluorescence value 10 mm from the inclusion and, subsequently, performed the dissection blinded to the location and depth of the
inclusions [Fig. 2(a)]. Using the Solaris to display fluorescence
over the surface of the phantom, the surgeon attempted to locate
and remove the inclusion with sufficient margins (10 mm)
[Fig. 2(b)]. Fifteen phantom dissections were performed for
both fat and muscle tissues (n ¼ 3 for each IBR). Surgical
cuts were made to the phantom, beginning on the outermost
aspects and progressing inward, to decrease the margins to
∼10 mm [Figs. 2(c) and 2(d)]. The stopping criteria included:
(1) the expected fluorescence signal was reached within
approximate dimensions of 4 cm × 4 cm × 4 cm [Figs. 2(e)
and 2(f)] or (2) the exposure of any part of the inclusion by
a surgical cut, thus representing a positive margin and failed
experiment. Each side of the remaining cuboids was imaged,
and the block was bisected in the horizontal and vertical planes.
Margin thickness of each phantom was measured by manual caliper, plotted against mean fluorescence for the varying tissue
types (fat and muscle) and IBRs (∞, 10∶1, 5∶1, 3∶1, and
2∶1), and compared to the targeted fluorescence values.

3
3.1

Results
Effect of Bulk Tissue Properties on Observed
Fluorescence Signal

The observed fluorescence of IRDye 800CW changes with
varying concentrations of absorbing (blood) and scattering
(intralipid) agents within the optical range of human connective
tissue, namely fat, muscle, and tumor (Fig. 3). The range of

Table 4 Surgical phantom parameters for margin thickness prediction and blinded dissection.

Background
Phantom type

Simulated tissue type

Inclusion

IRDye 800CW (nM)

IRDye 800CW (nM)

Starting depth (mm)

Horizontal location

0, 5, 10, 16.7, 25

50

30

Center

0, 5, 10, 16.7, 25

50

10, 20, 30

Random (surgeon blinded)

Muscle
Test

Fat
Muscle

Dissection
Fat

Journal of Biomedical Optics
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phantom conditions representing fat and muscle is indicated in
Fig. 3(a), and the specific conditions used throughout this study
for fat, muscle, and tumor/inclusion are circled. The fluorescence signal, normalized to the inclusion condition (1% blood
and 1% intralipid), was greatest in the 1.5% intralipid and 1.0%
blood condition [Fig. 3(b)]. The lowest signal had slightly less
than half the signal of the inclusion condition, arising from the
0.5% intralipid and 5.0% blood condition [Fig. 3(b)]. In general,
intralipid concentration was proportional to fluorescence, with a
plateau observed at the highest concentration (1.5%) [Fig. 3(c)].
In contrast, blood concentration (1.0% to 5.0% range) was
inversely proportional to fluorescence signal at all intralipid
concentrations, whereas a slight increase in fluorescence was
observed from 0.5% to 1.0% blood [Fig. 3(d)].

3.2

Effects of Phantom and Inclusion Properties on
Depth Sensitivity

The depth of imaging for phantoms with varying background
conditions is summarized in Table 6. At 0.5% intralipid, the
Solaris and Pearl imaging systems could detect fluorescence
emission from the inclusion at >3-cm depth at all blood concentrations; however, the Odyssey had much lower depth sensitivity with a maximum of 2.73 cm observed with 0% blood.
At a higher intralipid concentration (1% v/v), the Solaris and
Pearl had reduced depth sensitivity; however, both systems
could still detect fluorescence at depths >3 cm. In general, the
Pearl had greater depth sensitivity compared to the Solaris.
For all imaging systems and phantom properties, as the inclusion concentration increased, depth of imaging also increased
(Table 7). The Odyssey demonstrated the lowest depth sensitivity, with the smallest range in depth of imaging among concentrations. The Solaris and the Pearl displayed similar range in
depth sensitivity, but in general, the Pearl was more sensitive
to a greater depth.

Fig. 2 Blinded dissection of fluorescent inclusions (a, c, and e) in
white light and (b, d, and f) at 750 nm on the Solaris imaging system.
(a and b) Large cylindrical phantoms were created with a 10.6-cm3
inclusion randomly placed in the phantom. (c and d) The surgeon
(author E.R.H) used a circular ROI on the Solaris viewing screen
to locate the maximal fluorescence intensity and attempt to excise
the hidden inclusion. (e and f) The dissection was stopped when
the targeted fluorescence reading in the ROI was reached (Table 5)
with approximate dimensions of 4 cm × 4 cm × 4 cm. Scale bar ¼ 1
in. in all photos.

Table 5 Targeted and actual fluorescent values, and margin thicknesses for fat- and muscle-mimicking surgical phantom dissections.

Fluorescence signal (cps)
Target (Fit)
values

Fat

Muscle

Margin thickness (mm)

Actual
values

Actual
thickness

Background IRDye 800CW
concentration (nM)

Mean

SD

Mean

SD

Percent error

Target thickness

Mean

SD

Percent error

0

609

213

923

489

51.6

10

9.9

2.0

−0.8

5

1034

446

1381

434

33.6

10

11.2

2.0

11.9

10

2102

354

1978

307

−5.9

10

11.0

2.9

9.6

16.7

2490

89

2718

158

9.1

10

10.0

2.0

0.3

25

3466

282

4007

330

15.6

10

10.6

3.7

5.7

0

334

25

785

401

134.9

10

9.6

1.6

−4.2

5

950

117

1247

322

31.3

10

9.3

1.5

−7.1

10

1390

41

2155

457

55.1

10

8.4

1.6

−16.4

16.7

2046

147

2507

212

22.6

10

9.2

2.5

−7.7

25

2982

388

3124

317

4.8

10

8.9

1.8

−10.8

Journal of Biomedical Optics
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Fig. 3 Testing the observed fluorescence of IRDye 800CW based on bulk tissue properties of connective
tissues relevant to sarcoma. (a) Gelatin well phantoms with constant IRDye 800CW concentration
(50 nM) had varying intralipid (columns) and blood (rows) content. The range of properties for fat
(dashed) and muscle (dotted) is indicated. The individual circled wells indicate the tissue properties
used for fat (dashed), muscle (dotted), and tumor/inclusion (solid) throughout this study. (b) The fluorescence of each condition normalized to the tumor/inclusion fluorescence signal. (c) The effect of varying intralipid concentration on fluorescence signal. (d) The effect of varying blood concentration on
fluorescence signal.

Depth of imaging was proportional to inclusion size for the
infinite background condition when using the Pearl and Solaris
imaging systems; however, the Odyssey demonstrated a relatively constant penetration depth in all cases (Table 8).
Graphs demonstrating detection limits of the Pearl using fat
Table 6 Effect of background tissue properties on depth of imaging.

Depth of imaging (cm)
% Intralipid (v/v)
0.5

1.0

% Blood (v/v)

Solaris

Pearl

Odyssey

0

4.05

5.02

2.73

0.5

3.73

4.71

2.64

1.0

3.49

4.15

2.58

2.0

3.31

3.82

2.47

0

3.80

4.17

2.66

0.5

3.53

3.67

2.47

1.0

3.35

3.43

2.38

2.0

3.18

3.11

2.12

Journal of Biomedical Optics

phantoms with infinite and 3∶1 IBR can be seen in Fig. 4.
For the fat 3∶1 IBR, there was a proportional but small increase
in depth of imaging for all instruments when the inclusion size
was increased. In contrast, imaging depth in the muscle 3∶1 IBR
condition was inversely proportional to the inclusion size in the
Pearl and Solaris; however, the fluorescence plot profiles could
not be analyzed for the Odyssey because the natural logarithm of
the plot profiles did not intersect with the control case (0 mm)
for a positive depth value for each inclusion size. Overall, the
Pearl had the highest depth sensitivity, followed by the Solaris,
and then the Odyssey (Table 8).

3.3

Effects of Tissue Volume on Observed
Fluorescence Signal

The surgical “testing” phantoms were used to study the effects
of phantom volume on observed fluorescence intensity. In all
cases, the ROI was placed in the center of the phantom and
measurements were taken after every cut. We observed the
same trends for the Solaris and Pearl systems; therefore, the
Solaris data are presented in Fig. 5 (Pearl data not shown).
Initially, volume was removed from the upper surface of the
phantom in ∼5-mm increments reducing the height of the phantom [Figs. 5(a)–5(c)]. For both fat and muscle phantoms, the
maximum fluorescence intensities recorded for each individual
phantom occurred after the final slice was removed (closest to
121613-6
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Table 7 Effect of IRDye 800CW inclusion concentration on depth of
imaging. Columns labeled “fat” and “muscle” represent phantoms with
fat- and muscle-simulating wedge layers, respectively.

dissect the inclusion with a goal of 10-mm margins. The surgeon
was able to successfully dissect all surgical phantoms from
infinite to 2∶1 IBR without cutting into the inclusion. In all
cases, the surgeon was able to dissect close to the 10-mm margin
limit based solely on the provided fluorescence signals obtained
from the testing phantoms (Table 5 and Fig. 6). In general, the
margins on the fat phantoms were slightly larger than 10 mm but
had more spread in the data points, whereas the margins
obtained on the muscle phantoms were slightly lower than
10 mm and grouped more tightly [Fig. 6(a)]. The average margin fluorescence increased with increasing background florescence and was generally higher for fat than it was for muscle
[Table 5 and Fig. 6(b)]. Interestingly, the surgical dissection
phantoms generally displayed higher fluorescence intensities
than the surgical testing phantoms (Table 5).

Depth of imaging (cm)
Solaris

Pearl

Odyssey

Inclusion IRDye
800CW (nM)

Fat

Muscle

Fat

Muscle

Fat

Muscle

5

1.86

0.98

2.77

2.42

1.53

1.35

10

2.01

1.94

3.20

2.51

1.66

1.51

20

2.29

1.94

3.52

2.64

1.67

1.48

50

2.51

2.23

3.72

3.02

2.07

1.56

4
the inclusion), such that fluorescence increased with decreasing
volume. As the background fluorescence increased, the overall
fluorescence value also increased, such that the 2∶1 IBR (25-nM
background) phantom had the highest fluorescence, and the
infinite IBR (0-nM background) phantom had the lowest fluorescence. These data are demonstrated in the insets of Figs. 5(a)
and 5(b) for fat and muscle, respectively. When the fluorescence
intensities for each IBR phantoms were normalized to the initial
fluorescence reading, each IBR condition displayed a unique
curve, dependent on the depth to inclusion (as observed in
the wedge phantoms). However, when the depth was held constant and the volume reduced by removing gelatin from the sides
of the phantom, normalized fluorescence values decreased in
a similar fashion across all conditions, regardless of IBR and
observed fluorescence intensity [Figs. 5(d)–5(f)].

3.4

Discussion

The excision of sarcoma tumors with clear, negative margins
remains a challenge for oncologic surgeons. In light of recent
developments in FGS, ABY-029 is being tested as an EGFR-targeted agent capable of providing sufficient fluorescence contrast
to perform WLE of sarcoma tumors using indirect fluorescence
imaging methods. To test the ability of PerkinElmer’s Solaris
imaging system for surgical guidance to detect in vivo microdose levels of IRDye 800CW—the fluorescent agent covalently
bound to the anti-EGFR affibody agent—we compared its imaging capabilities to two commonly used preclinical systems
designed specifically for IRDye 800CW—the LI-COR Pearl
Impulse and the LI-COR Odyssey CLx. We have an extensive
history of using both of these instruments for in vivo and
ex vivo small rodent preclinical imaging studies using ABY029.27,28,31,32,46–49 Furthermore, the Odyssey CLx will be
used in the clinical trial of ABY-029 in sarcoma resection
(NCT03154411) to obtain high-resolution images of resected
tissue that could be up to several centimeters thick; thus, comparison of the depth of imaging of these systems is clinically
applicable.
The Solaris system is an open-air imaging system capable of
imaging in room lighting and has two channels (750 and
800 nm) that are able to image IRDye 800CW. The 750-nm
channel (743-nm short pass excitation and 770- to 809-nm

Surgical Phantom Dissection

The surgical testing phantoms with known inclusion location
were used to calculate target fluorescence values approximating
a margin thickness of 10 mm (Table 5). These values were
applied in a secondary study where the surgeon was blinded
to the location of the inclusion and used only the average fluorescence value across the surface of the phantom to localize and

Table 8 Effect of inclusion diameter on depth of imaging. Columns labeled “fat” and “muscle” represent phantoms with fat- and muscle-simulating
wedge layers, respectively. Columns labeled “∞” and “3∶1” represent phantoms with ∞ and 3∶1 inclusion-to-background contrast ratios,
respectively.

Depth of imaging (cm)
Solaris

Pearl

Fat

Muscle

Odyssey

Fat

Muscle

Fat

Muscle

∞

3∶1

∞

3∶1

∞

3∶1

∞

3∶1

∞

3∶1

∞

3∶1

4

2.60

2.34

2.02

1.71

3.55

1.66

2.32

1.57

2.89

1.54

1.15

—

6

2.85

2.47

2.12

1.16

3.74

1.75

2.78

1.42

2.67

1.57

1.32

—

8

2.99

2.53

2.21

1.14

4.08

2.06

2.92

1.48

2.80

1.64

1.38

—

13

3.21

2.70

2.33

1.13

4.29

2.18

3.06

1.38

2.89

1.72

1.43

—

17

3.14

2.80

2.35

1.11

4.44

2.28

2.99

1.36

2.89

1.75

1.47

—

Inclusion diameter (mm)
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Fig. 4 An example of determining detection limits for depth of imaging in fat wedge phantoms with varying inclusion sizes using the Pearl. (a) Infinite IBR: Left—plot profile from each wedge phantom with
varying inclusion size and right—the plot profiles are linearized and fit to determine depth of imaging
(interception with control condition, 0 mm). (b) 3∶1 IBR: Left—the plot profiles are shown as background
subtracted, where the background is the control 0-mm condition, and as the raw data (inset) and right—
linearized plot profiles of each inclusion size are fit to determine depth of imaging, where resolution limit is
when y ¼ 0.

emission) is suggested by the manufacturer and produces higher
intensity images. Comparatively, the Pearl is a black-box
imaging system with optical parameters tailored specifically
for IRDye 800CW, including a 785-nm excitation laser and
820-nm detection. The Odyssey is also specifically designed
to image IRDye 800CW and contains a 785-nm solid-state
diode laser excitation and silicon avalanche photodiode emission detection. The optical components of the Odyssey give
it incredible resolution and detection sensitivity with 4 logs of
dynamic range in manual mode. This allows the Odyssey to
obtain high-resolution, surfaced detailed images that can be
compared to histological and immunohistochemical tissue
sections. However, the laser beam is focused via microscope on
the surface of the imaging plane (or up to 4-mm depth) and,
thus, reducing light penetration into tissue and resultant fluorescence collection as compared to wide-field imaging.
As anticipated, in both fat- and muscle-mimicking tissue
phantoms, the Pearl outperformed both the Solaris and
Odyssey in depth detection of inclusions varying in size and
IRDye 800CW concentration. However, despite the decreased
performance of the Solaris in imaging depth and sensitivity, performance remained comparable to the Pearl—an achievement
likely obtained by proprietary background correction in the
Solaris software.38 Both the Pearl and the Solaris demonstrated
higher depth sensitivity than the Odyssey system, especially
at lower IRDye 800CW concentrations and inclusion sizes.
Journal of Biomedical Optics

Interestingly, the depth of imaging on the Odyssey scanner varied minimally over all conditions, especially in the inclusion size
study (Table 8). A similar effect has been observed previously
by our group when using a flat bed scanning system to image
fluorescent phantoms. In a previous study, we observed no
increase in fluorescence on a flat bed scanner when the diameter
of a fluorescent inclusion was increased50 while the broad beam
systems displayed a fluorescence increase. This suggests that the
flat bed scanning systems are highly surface weighted due to the
close proximity of the sample to both the excitation source and
detector and, therefore, do not probe the same depth and volume
as a broad beam system. However, flat bed scanners offer several
advantages, particularly in their reduced susceptibility to fluorescence blooming. While the specifications and uses of the
Solaris system differ from those of the Pearl and Odyssey, the
Solaris successfully performs as an advanced imaging system
adequate for clinical applications.
Connective tissues relevant to sarcoma resection have different optical properties (scattering and absorption),40 and the
Solaris system offers a wide range of imaging capabilities for
investigating the differences in these tissues. Nonlinear fluorescent effects occurred at intralipid concentrations >1%, and
fluorescence intensity substantially decreased with increasing
blood concentration >2%. For this reason, when testing depth
sensitivity relative to IRDye 800CW concentration and volume
(inclusion size), human muscle properties were selected at
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Fig. 5 Effects of volume on fluorescence intensity of a single ROI within the phantom. The change in
fluorescence intensity in (a) fat and (b) muscle phantoms as the height of the phantom is reduced (c) by
cutting downward toward the inclusion. Note the y -axis is in log format to visualize all IBR. The change in
fluorescence intensity in (d) fat and (e) muscle phantoms as (f) the sides of the phantom are removed
while the height of the phantom remains constant. In all cases, the inset shows nonnormalized data to
demonstrate the increase in overall intensity as background fluorescence increases (IBR decreases).

Fig. 6 Measured (a) margin thickness and (b) fluorescence intensity obtained by blinded surgical dissection of fat and muscle phantoms with increasing IBR.

the lower end range of blood volume.40–42 The properties chosen
for fat were moderate values, with both variables lower than that
of the inclusion parameters.40–42
In ideal imaging conditions, where the background tissue
contained no fluorophore and thus theoretically infinite inclusion contrast, the Solaris, Pearl, and Odyssey were able to
Journal of Biomedical Optics

resolve fluorescent inclusions deeper than 1 cm at all inclusion
sizes and IRDye 800CW concentrations, with the single exception of the Solaris when imaging muscle phantoms containing
the lowest concentration inclusions (5 nM). However, when
background fluorescence concentrations were increased to
achieve 3∶1 IBR, depth penetration in all systems was greatly
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reduced. In fact, in all cases, it was difficult to distinguish among
the various inclusion sizes and depth sensitivity in the muscle
3∶1 IBR condition tested on the Odyssey could not be resolved
at all. However, considering that most soft tissue sarcomas are
larger than the largest inclusion diameter tested here (17 mm)
and that contrast ratios ≥3 would be achieved, this limitation
is likely inconsequential in the clinical context.
In a previous study using surgical dissection phantoms with
background tissue conditions set at 1% blood and 1% intralipid,
we were able to successfully dissect inclusions with ∼1-cm margins with IBRs down to 3∶1.51 However, we were unsuccessful
in dissecting the 2∶1 IBR condition without cutting into the
inclusion. The reason for this is likely twofold: (1) as determined
in the present study, the 1% blood and 1% intralipid condition
has the highest observed fluorescence among the connective tissues, which would reduce contrast, and (2) the blinded surgeon
did not have a predetermined target fluorescence value as a stopping criteria. In this study, we advanced our previous techniques
using surgical testing phantoms to determine both the target
fluorescence value that would allow a surgeon to achieve
a 1-cm margin and by accounting for the effect of volume on
observed fluorescence. The volume effects are clinically relevant and especially important for the surgeon, because the fluorescence intensity increases exponentially as the surgeon cuts
toward the inclusion (reducing margin depth and overall phantom volume). However, once the desired fluorescence value is
achieved in the ROI, reducing the volume from the sides of the
phantom caused up to a 40% and 50% reduction in the observed
fluorescence value for fat and muscle, respectively. Thus, the
surgeon must strategize their incisions to account for the interplay between margin thickness and overall tissue volume to
achieve the desired margin.
Here, we demonstrated that a surgeon blinded to the location
of the inclusion was able to accurately dissect the fluorescent
inclusion with ∼1-cm margins in both fat and muscle phantom
conditions and at all contrast ratios by knowing only the predetermined fluorescence value for our desired margin thickness.
The largest spreads in achieved margin thicknesses were in the
5∶1 to 2∶1 contrast conditions. Conversely, the largest spreads
in final fluorescence intensities were in the infinite and 10∶1
IBR cases. This is likely due to the exponential fashion in
which light is attenuated as it travels through tissue. In higher
contrast cases, removing small amounts of tissue resulted in
large changes in fluorescence, whereas the opposite is true
for lower contrast cases. When there is less contrast, large
amounts of tissue need to be removed to observe a substantial
increase in fluorescence, making a consistent and accurate dissection more difficult. These data indicate the importance of
determining tumor fluorophore uptake and binding prior to surgery, to account for tumor contrast while performing surgical
resection.
The inability to accurately resolve target structures at low
tumor-to-background ratios (TBR) is a concern for FGS, especially in the case of WLE where the goal is to remove tumor bulk
and achieve a tumor-free margin simultaneously. Human trials
have been performed using a single-fluorescent-targeted antibody (cetuximab-IRDye 800CW) for resection using FGS of
head and neck squamous cell carcinomas.9 Although this
first-in-human study demonstrated modest TBRs (∼4.3), antibody-based FGS suffers, in general, from long injection-toresection times on the order of days. This is thought to be
the result of a complex combination of very slow plasma
Journal of Biomedical Optics

clearance (hours to days), receptor binding and cellular internalization, vascular density and perfusion, and inhibited lymphatic clearance.9 To overcome the limitation of suboptimal
contrast, “cold doses” (subtherapeutic dose of naïve antibody)
administered prior to the imaging antibody were investigated to
deplete endogenous receptor “sinks” and increase contrast,
although this was met with limited further enhancement
(TBR ∼5.5).39 The present study validates that any TBR ≥ 2
is sufficient to achieve desired margins when prior knowledge
of the inclusion is known. However, using a small, targeted molecule, such as ABY-029, which will clear from the vasculature at
a faster rate (minutes to hours)25 will ultimately reduce the administration-to-resection times, increase tumor contrast, and
improved the accuracy of margin assessment.

5

Conclusions

FGS is a promising tool for surgical resection of many cancers;
however, resection of subsurface tumors is not currently
amenable to the conventional direct fluorescence visualization
techniques. This study validates our ability to use indirect, subsurface fluorescence measures to successfully resect a tumormimicking inclusion to a predetermined margin thickness
using predicted fluorescence readings specific for the surgical
instrument of choice. Further studies using light modeling to
combine prior knowledge of tissue characteristics (background
tissue optical properties, tissue pharmacokinetics, tumor size/
shape/volume, and tumor EGFR concentration/expression)
could be used to predict target fluorescence values equivalent
to a desired margin thickness on a patient-to-patient basis.
Additionally, maximizing the tumor-to-background tissue
contrast ratios by carefully selecting the imaging agent and
administration-to-imaging times will improve accuracy and
repeatability of obtaining a clear margin of known thickness.
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